Total Payments
$10,745
2024 Payments
$1,132
Companies
44
Transactions
546
Medicare Patients
1,216
Medicare Billing
$464,803
Payment Breakdown by Category
Food & Beverage$9,596 (89.3%)
Education$1,149 (10.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,596 | 517 | 89.3% |
| Education | $1,149 | 29 | 10.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $1,300 | 73 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,166 | 59 | $0 (2024) |
| Janssen Biotech, Inc. | $1,118 | 45 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,084 | 57 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $861.25 | 58 | $0 (2024) |
| Seagen Inc. | $568.10 | 22 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $467.67 | 34 | $0 (2021) |
| Amgen Inc. | $456.71 | 20 | $0 (2023) |
| Incyte Corporation | $405.59 | 17 | $0 (2024) |
| Celgene Corporation | $397.86 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,132 | 47 | Janssen Biotech, Inc. ($284.26) |
| 2023 | $1,944 | 88 | AstraZeneca Pharmaceuticals LP ($338.44) |
| 2022 | $1,781 | 89 | AstraZeneca Pharmaceuticals LP ($249.50) |
| 2021 | $1,121 | 51 | AbbVie Inc. ($245.41) |
| 2020 | $1,095 | 52 | Novartis Pharmaceuticals Corporation ($173.82) |
| 2019 | $1,307 | 78 | PFIZER INC. ($224.67) |
| 2018 | $1,010 | 61 | PFIZER INC. ($306.93) |
| 2017 | $1,355 | 80 | PFIZER INC. ($233.99) |
All Payment Transactions
546 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Oncology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: Oncology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $29.06 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | DARZALEX (Drug) | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.50 | General |
| Category: Hematology/Oncology | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $29.69 | General |
| Category: Immunology | ||||||
| 10/08/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $32.65 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: Immunology | ||||||
| 09/30/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $25.39 | General |
| Category: Oncology | ||||||
| 09/16/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $27.47 | General |
| Category: Immunology | ||||||
| 08/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $31.87 | General |
| Category: Immunology | ||||||
| 07/25/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $14.03 | General |
| 07/11/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.49 | General |
| Category: Oncology | ||||||
| 07/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $1.94 | General |
| Category: Oncology | ||||||
| 06/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Oncology | ||||||
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.41 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Immunology | ||||||
| 05/30/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.22 | General |
| Category: Hematology | ||||||
| 05/24/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 275 | 1,067 | $108,390 | $75,783 |
| 2022 | 9 | 246 | 1,069 | $108,400 | $76,723 |
| 2021 | 8 | 284 | 1,490 | $137,829 | $102,842 |
| 2020 | 13 | 411 | 10,453 | $280,998 | $209,455 |
Total Patients
1,216
Total Services
14,079
Medicare Billing
$464,803
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 46 | 289 | $32,240 | $23,123 | 71.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 158 | $24,950 | $17,388 | 69.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 17 | 173 | $14,350 | $10,568 | 73.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 48 | $12,960 | $7,437 | 57.4% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 51 | 58 | $9,140 | $6,854 | 75.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 291 | $7,770 | $5,545 | 71.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $3,910 | $2,626 | 67.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 18 | $1,570 | $1,222 | 77.8% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 13 | 16 | $1,500 | $1,020 | 68.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 267 | $30,725 | $22,158 | 72.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 194 | $30,987 | $22,152 | 71.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 18 | 162 | $14,623 | $10,765 | 73.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 44 | 46 | $11,070 | $8,365 | 75.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 19 | 305 | $9,140 | $6,147 | 67.3% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Facility | 2022 | 27 | 28 | $6,000 | $3,288 | 54.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 24 | $2,040 | $1,593 | 78.1% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 13 | 19 | $2,190 | $1,217 | 55.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 24 | $1,625 | $1,037 | 63.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 63 | 215 | $32,649 | $23,787 | 72.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 29 | 261 | $29,621 | $22,260 | 75.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 17 | 255 | $23,243 | $18,301 | 78.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 65 | 74 | $17,885 | $13,069 | 73.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 139 | $11,815 | $9,303 | 78.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis | Office | 2021 | 17 | 434 | $13,207 | $9,240 | 70.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 39 | 101 | $6,689 | $4,869 | 72.8% |
About Dr. Geeta George, MD
Dr. Geeta George, MD is a Hematology & Oncology healthcare provider based in Peekskill, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548344500.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Geeta George, MD has received a total of $10,745 in payments from pharmaceutical and medical device companies, with $1,132 received in 2024. These payments were reported across 546 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($9,596).
As a Medicare-enrolled provider, George has provided services to 1,216 Medicare beneficiaries, totaling 14,079 services with total Medicare billing of $464,803. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Peekskill, NY
- Active Since 10/25/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548344500
Products in Payments
- OPDIVO (Biological) $774.25
- IBRANCE (Drug) $490.27
- GILOTRIF (Drug) $467.67
- IMBRUVICA (Drug) $448.21
- DARZALEX (Biological) $443.91
- IMFINZI (Biological) $394.53
- ADCETRIS (Biological) $381.56
- PROMACTA (Drug) $330.55
- JAKAFI (Drug) $305.64
- IMFINZI (Drug) $283.96
- VENCLEXTA (Drug) $245.41
- TAGRISSO (Drug) $224.88
- KISQALI (Drug) $202.62
- Fabhalta (Drug) $189.57
- PIQRAY (Drug) $177.62
- SUTENT (Drug) $165.66
- XTANDI (Drug) $164.54
- Lonsurf (Drug) $164.40
- KEYTRUDA (Biological) $159.37
- REBLOZYL (Biological) $159.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.